SWK Holdings Corp. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual filing, not a standalone fourth-quarter report; the filing’s portfolio table reports Q4 investment income of $4.158 million, but does not provide a clear standalone Q4 income statement.
Business context
SWK provides specialty financing to life-science businesses, primarily through loans backed by royalties or product revenues, royalty purchases and revenue interests. It also advises institutional clients through separately managed accounts. At year-end, its portfolio included $126.4 million of finance receivables, $2.6 million of marketable investments and a $7.0 million investment in an unconsolidated entity.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $22.380 million | $23.460 million |
| Income (loss) before tax | $10.403 million | $(1.090) million |
| Net income (loss) attributable to SWK shareholders | $28.888 million; $2.22 per diluted share | $(7.370) million; $(0.57) per diluted share |
| Net cash provided by operating activities | $9.643 million | $11.209 million |
Revenue declined 4.6% year over year. Interest and fees on finance receivables and marketable securities were $15.839 million; income related to the unconsolidated entity was $6.219 million. The reported net profit was materially affected by a $21.638 million income-tax benefit, primarily reflecting a reduction in the deferred-tax valuation allowance; it should not be read as recurring operating earnings. The filing reports no separate profit margin.
Costs included a $1.659 million provision for loan credit losses and $8.077 million of security impairment expense. General and administrative expense was $2.829 million, down from $3.378 million; interest expense was zero. At year-end, cash and cash equivalents were $32.182 million, total assets $208.932 million, total liabilities $0.871 million and total equity $208.061 million. Cash fell $15.105 million during the year; investing cash flow was $(21.052) million and financing cash flow was $(3.696) million. SWK reported no current credit facility or other borrowing access.
Changes, outlook and key risks
- Shareholder-attributable results swung from a $7.370 million loss to $28.888 million of income, substantially due to the tax benefit. Revenue decreased as repayments and dispositions and loans placed on nonaccrual offset income from new and additional lending.
- Significant credit and valuation items included a $5.3 million impairment on the sale of SynCardia assets, a $1.7 million Besivance royalty allowance, and impairments associated with a women’s-health royalty financing and Cancer Genetics equity. Two term loans totaling $19.0 million were on nonaccrual at year-end; no cash was collected on nonaccrual loans during 2016.
- Management expected current-portfolio income to exceed operating expenses and anticipated book-value growth, while noting that the timing and completion of new investments were uncertain. Management believed available funds and alternative sources would cover current commitments; unfunded commitments totaled $10.6 million.
- After year-end, Holmdel sold substantially all its assets; SWK received approximately $8.0 million in net proceeds in February 2017. The filing also reports a $3.75 million contingent Narcan earnout if specified sales conditions are met.
- Key risks include concentrated exposure to a small number of life-science borrowers and products, defaults and collateral recovery, product sales and regulatory or reimbursement changes, competition, limited access to additional financing, and reliance on key personnel. Two partner companies generated 41% of 2016 revenue. Carlson-affiliated funds held approximately 69% of specified combined share and warrant interests and had significant influence rights.
- SWK reported $404.0 million of federal NOL carryforwards, most expiring by 2021, and cautioned that it may not use them all. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness.
Investor verification priorities
- Reconcile the $28.9 million shareholder profit to the $21.6 million tax benefit and assess the sustainability of earnings without that benefit.
- Review borrower-level performance, collateral valuations and recovery assumptions for the $19.0 million of nonaccrual loans and other impaired exposures.
- Verify the post-year-end Holmdel proceeds, the treatment and timing of contingent payments, and the status of the $10.6 million unfunded commitments.
- Assess liquidity and growth capacity given the year-end cash balance, absence of a credit facility, portfolio concentration and reliance on future financing or managed capital.
- Evaluate the potential usability and expiration limits of NOLs, along with ownership-change restrictions under tax law.